Vildagliptin API Manufactured by GMP Manufacturers

Vildagliptin is another orally administered dipeptidyl peptidase-IV (DPP-IV) inhibitor after sitagliptin. Approved in the European Union for the treatment of type 2 diabetes. Diabetes mellitus is a chronic metabolic disease, and its prevalence is increasing year by year. Type 2 diabetes is a complex disease caused by the combined effects of multiple genetic factors and environmental factors. Dipeptidyl peptidase IV (DPP-IV) Chemicalbook inhibitors are a new class of anti-diabetic drugs that induce and promote biosynthesis and secretion, inhibit β-cell apoptosis, inhibit glucagon secretion, and reduce food intake, etc. A variety of mechanisms play a role in lowering blood sugar, and while controlling blood sugar, it can reverse the continuous deterioration of islet function in diabetic patients, showing a good application prospect. Vildagliptin is a representative drug of dipeptidyl peptidase inhibitor. It has shown good anti-diabetic effect and tolerance in clinical studies, whether alone or in combination with metformin and i*nsulin.